Positions:
Prof. Michal Mandelboim is the head of the National Center for Influenza and Respiratory Viruses at the Central Virus Laboratory of the Ministry of Health, at Sheba Tel Hashomer Medical Center. She is Associate Professor at the Department of Epidemiology and Preventive Medicine, at the School of Medicine, at Tel Aviv University.
General:
As the director of the National Influenza Center, I am part of the World Health Organization (WHO), as the representative of Israel. My laboratory focuses on developing new methods for the identification, diagnosis, treatment, vaccination and monitoring of respiratory viruses infections.
We perform epidemiological studies as well as basic research on the mode of infection of respiratory viruses and their pathogenesis.
We study a large number of respiratory viruses including influenza viruses, Respiratory Syncytial Virus (RSV), Human Metapneumovirus (hMPV), Parainfluenza viruses, human corona viruses such as: MERS, NL63, OC43, 229E, HKU1 and of course the SARS-CoV-2 virus. For my research work, I won the Serov prize for clinical virology.
The importance of my research was most evidently demonstrated during the COVID-19 pandemic. We identified the first patient in Israel and were among the few laboratories in the world capable of growing the original virus and its various variants. My work influenced the vaccination policy in locally and globally, and had a critical impact on the policy of the Ministry of Health in the context of developing methods to identify the virus and the vaccination policy of the population.
To date I have published around 180 articles, I have been invited to lecture at many conferences and I have many collaborations with clinicians in Israel and the world related to treatment, understanding the disease and vaccines.
Publications:
Link to the full publication list in PubMed
https://pubmed.ncbi.nlm.nih.gov/?term=mandelboim+m&sort=date&show_snippets=off
Selected articles out of ~180
1) Moss S, Jurkowicz M, Nemet I, Atari N, Kliker L, Abd-Elkader B, Gonen T, Martin ET, Lustig Y, Regev-Yochay G, Mandelboim M. Immunogenicity of Co-Administered Omicron BA.4/BA.5 Bivalent COVID-19 and Quadrivalent Seasonal Influenza Vaccines in Israel during the 2022-2023 Winter Season. Vaccines (Basel). 2023;11(10):1624. doi: 10.3390/vaccines11101624.PMID: 37897026
2) Peled Y, Afek A, Patel JK, Raanani E, Segev A, Ram E, Fardman A, Beigel R, Atari N, Kliker L, Elkader BA, Mandelboim M. Fifth bivalent omicron BA.4/BA.5 vaccination neutralization of SARS-CoV-2 in heart transplant recipients. J Heart Lung Transplant. 2023 Aug;42(8):1054-1058. doi: 10.1016/j.healun.2023.03.016. PMID: 37084801; PMCID: PMC10112987.
3) Atari N, Kliker L, Zuckerman N, Elkader BA, Weiss-Ottolenghi Y, Mendelson E, Kreiss Y, Regev-Yochay G, Mandelboim M. Omicron BA.2.75 variant is efficiently neutralised following BA.1 and BA.5 breakthrough infection in vaccinated individuals, Israel, June to September 2022. Euro Surveill. 2022;27(44):2200785. doi: 10.2807/1560-7917.ES.2022.27.44.2200785. PMID: 36330820; PMCID: PMC9635020.
4) Peled Y, Afek A, Kreiss Y, Rahav G, Nemet I, Kliker L, Indenbaum V, Ram E, Lavee J, Segev A, Matezki S, Sternik L, Raanani E, Lustig Y, Patel JK, Mandelboim M. Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients - implications for the omicron variant. J Heart Lung Transplant. 2022;41(10):1417-1425. doi: 10.1016/j.healun.2022.05.014.PMID: 35710483)
5) Kliker L, Zuckerman N, Atari N, Barda N, Gilboa M, Nemet I, Abd Elkader B, Fratty IS, Jaber H, Mendelson E, Alroy-Preis S, Kreiss Y, Regev-Yochay G, Mandelboim M. COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022. Euro Surveill. 2022;27(30):2200559. doi: 10.2807/1560-7917.ES.2022.27.30.2200559.PMID: 35904058
6) Rahav G, Maimon N, Halperin R, Nemet I, Kreiss Y, Afek A, Mandelboim M. Is Now the Time for the Fourth BNT162b2 Dose for Residents of Long-term Care Facilities? J Gerontol A Biol Sci Med Sci. 2022;77(7):1380-1381. doi: 10.1093/gerona/glac044.PMID: 35192714
7) Stein M, Cohen H, Nemet I, Atari N, Kliker L, Fratty IS, Bucris E, Geva M, Mendelson E, Zuckerman N, Mandelboim M. Human metapneumovirus prevalence during 2019-2021 in Israel is influenced by the COVID-19 pandemic..Int J Infect Dis. 2022;120:205-209. doi: 10.1016/j.ijid.2022.04.037.
8) Glatman-Freedman A, Gur-Arie L, Sefty H, Kaufman Z, Bromberg M, Dichtiar R, Rosenberg A, Pando R, Nemet I, Kliker L, Mendelson E, Keinan-Boker L, Zuckerman NS, Mandelboim M; Israeli Respiratory Viruses Surveillance Network (IRVSN). The impact of SARS-CoV-2 on respiratory syndromic and sentinel surveillance in Israel, 2020: a new perspective on established systems. Euro Surveill. 2022;27(16):2100457. doi: 10.2807/1560-7917.ES.2022.27.16.2100457.PMID: 354513659:
9) Nemet I, Kliker L, Lustig Y, Zuckerman N, Erster O, Cohen C, Kreiss Y, Alroy-Preis S, Regev-Yochay G, Mendelson E, Mandelboim M. Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection. N Engl J Med. 2022 Feb 3;386(5):492-494. doi: 10.1056/NEJMc2119358. Epub 2021 Dec 29.PMID: 34965337
10) Zuckerman N, Nemet I, Kliker L, Atari N, Lustig Y, Bucris E, Bar Ilan D, Geva M, Sorek-Abramovich R, Weiner C, Rainy N, Bar-Chaim A, Benveniste-Levkovitz P, Abu Hamed R, Regev-Yochay G, Hevkin O, Mor O, Alroy-Preis S, Mendelson E, Mandelboim M. The SARS-CoV-2 Lambda variant and its neutralisation efficiency following vaccination with Comirnaty, Israel, April to June 2021.Euro Surveill. 2021;26(45):2100974. doi: 10.2807/1560-7917.ES.2021.26.45.2100974.PMID: 34763751
11) Lustig Y, Zuckerman N, Nemet I, Atari N, Kliker L, Regev-Yochay G, Sapir E, Mor O, Alroy-Preis S, Mendelson E, Mandelboim M. Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel. Euro Surveill. 2021;26(26):2100557. doi: 10.2807/1560-7917.ES.2021.26.26.2100557.PMID: 34212838
12) Lustig Y, Nemet I, Kliker L, Zuckerman N, Yishai R, Alroy-Preis S, Mendelson E, Mandelboim M. Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2. N Engl J Med. 2021 Jun 24;384(25):2453-2454. doi: 10.1056/NEJMc2104036. Epub 2021 Apr 7.PMID: 33826815
13) Gerchman Y, Mamane H, Friedman N, Mandelboim M. UV-LED disinfection of Coronavirus: Wavelength effect. J Photochem Photobiol B. 2020;212:112044. doi: 10.1016/j.jphotobiol.2020.112044. Epub 2020 Sep 28.PMID: 33022467
14) Kustin T, Ling G, Sharabi S, Ram D, Friedman N, Zuckerman N, Bucris ED, Glatman-Freedman A, Stern A, Mandelboim M. A method to identify respiratory virus infections in clinical samples using next-generation sequencing. Sci Rep. 2019;9(1):2606. doi: 10.1038/s41598-018-37483-w.PMID: 30796243